Search clinical trials for: Pharmacokinetics, interaction, QAB149, indacaterol, ketoconazole, healthy subjects

Total 40056 results

Novartis Pharmaceuticals

Completed

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis

Completed

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis

Completed

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

Healthy

India
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Asthma
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis

Completed

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Novartis Pharmaceuticals

Completed

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Romania, Hungary, Bulgaria, Spain, Finland, Puerto Rico
Novartis Pharmaceuticals

Completed

Dose Ranging Study for Indacaterol in Japanese Asthma Patients

Asthma

Japan
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Asthma

Italy, Germany, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Netherlands, Canada, United States
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis Pharmaceuticals

Completed

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (SYNERGY)

Chronic Obstructive Pulmonary Disease: COPD

Switzerland
Kowa Research Institute, Inc.

Withdrawn

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Dyslipidemia | Hyperlipidemia

United States
Novartis

Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, Belgium, Spain, Turkey, Italy, Canada, Australia
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia, Puerto Rico
AstraZeneca

Completed

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Pharmacokinetics | Relative Bioavailability | AUC | Cmax

United States
AstraZeneca

Completed

Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.

Asthma, | Pharmacokinetics, | Cmax, | Tmax, | λz, | AUC, | Ketoconazole, | Metabolite

United Kingdom
Astellas Pharma Inc

Completed

To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol

Healthy Subjects | Pharmacokinetics of Mirabegron

Netherlands
AstraZeneca

Completed

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability (PK Combination)

Pharmacokinetics

United States
GlaxoSmithKline

Completed

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.

Healthy Subjects

United States
GlaxoSmithKline

Completed

An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.

Healthy Subjects

United States
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Not yet recruiting

Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects

Acne Vulgaris
Tonghua Dongbao Pharmaceutical Co.,Ltd

Recruiting

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects

Healthy

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects

Systemic Lupus Erythematosus

China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects

Lipoprotein Disorder Disease
Spot Biosystems Ltd.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Not yet recruiting

Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects

Skin Aging
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Overweight or Obesity; Type 2 Diabetes

China
Gannex Pharma Co., Ltd.

Not yet recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy Subjects

NASH
Zhuhai Beihai Biotech Co., Ltd

Not yet recruiting

An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects

Bioavailability
University of North Carolina, Chapel Hill
Environmental Protection Agency (EPA)

Not yet recruiting

Craniofacial Dimensions as Determinants of the Fitted Performance of Common Face Masks (FACEFIT 2.0)

Healthy

United States
Bostal Drug Delivery Co., Ltd

Not yet recruiting

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

Diabetes Mellitus, Type 2
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects

Type 2 Diabetes Mellitus

China
Aventure AB
Lund University; Carbiotix AB

Recruiting

The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health (SEAPRO01)

Healthy Subjects

Sweden
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Chronic Obstructive Pulmonary Disease

China
University of Bologna

Not yet recruiting

Effect of a Dietary Supplement on Lipid Pattern, Indexes of NAFLD and Systemic Inflammation in Healthy Subjects With Suboptimal LDL-C Levels

Inflammation | Hypercholesterolemia

Italy

3

Subscribe